ArticleJournal of orthopaedic case reports2026
Clinicoradiological Outcomes after Percutaneous Radiofrequency Ablation of Benign Bone Tumors: A Prospective Observational Study.
Article in Journal of orthopaedic case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Radiofrequency ablation (RFA) is a minimally invasive technique for the treatment of benign bone tumors, offering pain relief and lesion control with minimal morbidity. However, prospective Indian data on clinicoradiological outcomes remain sparse. This study aimed to evaluate pain reduction, functional recovery, and radiological healing following RFA in benign bone tumors. Materials and Methods: This prospective study included 25 patients with symptomatic benign bone tumors who underwent percutaneous RFA under spinal anesthesia between 2017 and 2020. RFA was performed under C-arm or computed tomography (CT) guidance. Pain was assessed using the visual analogue scale (VAS) and functional outcome through the musculoskeletal tumor society (MSTS) score at baseline, 3 weeks, 6 weeks, and 6 months. Imaging follow-up with X-ray, CT, and magnetic resonance imaging (MRI) evaluated lesion size and marrow edema. Statistical significance was set at P < 0.05. Results: The mean pre-procedural VAS score was 7.44 ± 0.3, which reduced to 0.68 at 6 months (P < 0.05). MSTS scores improved from a baseline of 28.73-35 (maximum) by the 3rd week and remained stable thereafter. Radiologically, the mean lesion diameter decreased from 1.67 cm to 0.95 cm at 3 months (P = 0.005). Complete lesion resolution on CT was observed in 83.3% at 6 months and 95.8% at 9 months. MRI demonstrated resolution of marrow edema in 96% of cases. Minor complications included two superficial burns and one recurrence requiring surgical curettage. There were no infections, fractures, or significant adverse events. Conclusion: RFA is a safe and effective outpatient procedure for benign bone tumors, providing rapid and sustained pain relief, excellent functional outcomes, and high rates of radiological resolution. These results affirm RFA as a valuable alternative to surgical excision in appropriately selected cases. Larger studies are warranted to validate these findings and explore long-term outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.